Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609200 | 0.83 | BRD4 (0.44) | BRD4CAMKK2FYN | |
| SCHEMBL8321910 | 0.81 | CAMKK2 (0.42) | BRD4CAMKK2FYNMAOBPTGS2 | |
| SCHEMBL1487602 | 0.80 | BRD4 (0.56) | BRD4CAMKK2FYNPTGS2IGF1R | |
| SCHEMBL13745928 | 0.79 | CAMKK2 (0.41) | BRD4CAMKK2FYNMAOBPTGS2 | |
| SCHEMBL13609249 | 0.76 | CAMKK2 (0.45) | BRD4CAMKK2FYNIGF1R | |
| SCHEMBL1487961 | 0.73 | CAMKK2 (0.67) | CAMKK2IGF1R | |
| SCHEMBL13745693 | 0.71 | FYN (0.41) | BRD4CAMKK2FYNMAOBPTGS2 | |
| SCHEMBL13745654 | 0.70 | BRD4 (0.55) | BRD4CAMKK2MAOB | |
| SCHEMBL8325104 | 0.70 | BRD4 (0.60) | BRD4MAOBGRM5 | |
| SCHEMBL1487576 | 0.70 | HTR6 (0.45) | BRD4CAMKK2FYNPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | BRD4 469/4885CAMKK2 83/4885FYN 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.